MX2022006500A - Terapia de combinacion que involucra compuestos macrociclicos de diarilo. - Google Patents

Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Info

Publication number
MX2022006500A
MX2022006500A MX2022006500A MX2022006500A MX2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A
Authority
MX
Mexico
Prior art keywords
combination therapy
macrocyclic compounds
therapy involving
diaryl
diaryl macrocyclic
Prior art date
Application number
MX2022006500A
Other languages
English (en)
Inventor
Wei Deng
Dayong Zhai
Jingrong J Cui
Laura Rodon
Brion W Murray
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2022006500A publication Critical patent/MX2022006500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a los métodos y las composiciones utilizados para el tratamiento de cáncer con el macrociclo de diarilo en combinación con un inhibidor KRAS, tal como un inhibidor de KRAS G12C.
MX2022006500A 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo. MX2022006500A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US202063005681P 2020-04-06 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
MX2022006500A true MX2022006500A (es) 2022-07-04

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006500A MX2022006500A (es) 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Country Status (12)

Country Link
US (2) US11654145B2 (es)
EP (1) EP4065125A4 (es)
JP (1) JP2023505056A (es)
KR (1) KR20220133866A (es)
CN (1) CN114901286B (es)
AU (1) AU2020391222A1 (es)
BR (1) BR112022010278A2 (es)
CA (1) CA3162632A1 (es)
IL (1) IL293206A (es)
MX (1) MX2022006500A (es)
TW (1) TW202133855A (es)
WO (1) WO2021108682A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168648A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
BR112023018734A2 (pt) * 2021-03-17 2023-10-24 Amgen Inc Regimes de dosagem de sotorasib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060328A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
ES2735729T3 (es) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10316044B2 (en) * 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
BR112018008357A2 (pt) * 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
HUE061599T2 (hu) 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
JP2022500381A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CA3163095A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
EP4065125A1 (en) 2022-10-05
US20240033266A1 (en) 2024-02-01
AU2020391222A1 (en) 2022-06-30
CA3162632A1 (en) 2021-06-03
TW202133855A (zh) 2021-09-16
CN114901286B (zh) 2024-05-10
JP2023505056A (ja) 2023-02-08
IL293206A (en) 2022-07-01
WO2021108682A1 (en) 2021-06-03
US20210220364A1 (en) 2021-07-22
EP4065125A4 (en) 2024-01-03
US11654145B2 (en) 2023-05-23
CN114901286A (zh) 2022-08-12
KR20220133866A (ko) 2022-10-05
BR112022010278A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2022004656A (es) Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
PH12019501328A1 (en) 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MY196830A (en) Kras g12c inhibitors and methods of using the same
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
AU2018238202A8 (en) Combination therapy for the treatment or prevention of tumours
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2021002805A (es) Terapias de combinacion.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX368261B (es) Letalidad sintetica y el tratamiento de cancer.
WO2023235807A3 (en) Method and compositions for treating glioblastoma with triterpenes